CD4 and inflammatory bowel disease: Reassuringly, robust responses in infliximab-treated IBD patients are achieved post vaccination, as the total Spike-specific CD4+ and CD8+ T cells quantified in isolated PBMCs 3 weeks after a single dose [53] and 2 weeks following two doses were comparable to healthy adults [54].